{
    "clinical_study": {
        "@rank": "16721", 
        "arm_group": {
            "arm_group_label": "KTN3379", 
            "arm_group_type": "Experimental", 
            "description": "KTN3379"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the pharmacokinetic profile and safety of KTN3379 over several\n      doses with the objective of defining a Phase 2 dose in patients with advanced malignancies.\n      Additional patients may be enrolled at the defined recommended Phase 2 dose to obtain\n      additional safety, pharmacokinetic and biomarker information. Patients will continue\n      receiving KTN3379 until disease progression or toxicity that necessitates discontinuation\n      (whichever comes first)."
        }, 
        "brief_title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Cancer", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Major Inclusion Criteria:\n\n          -  Histologically- or cytologically-confirmed advanced solid tumors that are refractory\n             to standard therapy or for which no standard therapy exist.\n\n          -  Eastern Cooperative Oncology Group (ECOG) status of 0 or 1\n\n          -  Adequate organ function as defined below:\n\n               -  Hemoglobin \u2265 9 g/dL\n\n               -  Absolute neutrophil count \u2265 1500/mm3\n\n               -  Platelet count \u2265 100,000/mm3\n\n               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u2264 5 \u00d7\n                  institutional upper limit of normal (ULN) for cases involving liver metastasis\n                  and \u2264 2.5 \u00d7ULN for all other cases\n\n               -  Bilirubin \u2264 1.5 \u00d7 ULN except for cases of documented or suspected Gilbert's\n                  disease, in which bilirubin must be \u2264 5 \u00d7 ULN\n\n               -  Serum creatinine \u2264 1.5 g/dL\n\n          -  Measurable disease by RECIST\n\n          -  Females must be surgically sterile, one year post menopausal or negative results for\n             a pregnancy test performed at Screening and agree to use two methods of\n             contraception; Males who have not had a vasectomy must agree to two methods of\n             contraception\n\n        Major Exclusion Criteria:\n\n          -  Receipt of anticancer therapy:\n\n               -  within 3 weeks prior to the first dose of KTN3379, or\n\n               -  within 6 weeks or 7 half lives prior to the first dose of KTN3379 in the case of\n                  anticancer therapy involving MAbs, or\n\n               -  within 2 weeks prior to the first dose of KTN3379 in the case of palliative\n                  radiation therapy.\n\n          -  Symptomatic or untreated central nervous system metastases requiring concurrent\n             treatment, including but not limited to surgery, radiation, and/or corticosteroids;\n             if treated, subject must be asymptomatic for 3 months prior to study entry\n\n          -  Subjects who are known to have a history of or active human immunodeficiency virus\n             (HIV) or active hepatitis B and/or C\n\n          -  Uncontrolled intercurrent illness including but not limited to ongoing or active\n             infection, symptomatic congestive heart failure, uncontrolled hypertension,\n             uncontrolled or idiopathic hypotension, unstable angina pectoris, cardiac arrhythmia\n             including atrial fibrillation, active peptic ulcer disease or gastritis, or\n             psychiatric illness/social situations that would limit compliance with study\n             requirements or compromise the ability of the subject to give written informed\n             consent\n\n          -  Any condition that, in the opinion of the investigator, would interfere with\n             evaluation of the investigational product or interpretation of subject safety or\n             study results\n\n          -  Subjects with a left ventricular cardiac ejection fraction < 50% as assessed by an\n             echocardiogram or MUGA scan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014909", 
            "org_study_id": "KTN3379-CL-001"
        }, 
        "intervention": {
            "arm_group_label": "KTN3379", 
            "description": "IV until progression or unacceptable toxicity; initial dose escalation followed by expansion", 
            "intervention_name": "KTN3379", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "KTN3379", 
            "Advanced cancer", 
            "Phase 1", 
            "Monoclonal antibody", 
            "Safety and pharmacokinetics"
        ], 
        "lastchanged_date": "December 18, 2013", 
        "location": [
            {
                "contact": {
                    "email": "danielle.wanik@yale.edu", 
                    "last_name": "Danielle Wanik"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06510"
                    }, 
                    "name": "Yale Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Joseph Paul Eder, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "grambushj@karmanos.org", 
                    "last_name": "Jordan Grambush"
                }, 
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }, 
                    "name": "Barbara Ann Karmanos Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Patricia Lorusso, DO", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors", 
        "overall_official": [
            {
                "affiliation": "Yale University", 
                "last_name": "Joseph Paul Eder, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Barbara Ann Karmanos Cancer Institute", 
                "last_name": "Patricia Lorusso, DO", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Continued assessment of safety", 
            "measure": "Maximum tolerated dose and dose limiting toxicities for Phase 2 dose and schedule", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed for the duration of treatment, an expected average of 3 cycles/9 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014909"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Area Under the Concentration-Time Curve (AUC 0 through end of study)", 
            "safety_issue": "No", 
            "time_frame": "Prior to the initial dose on day 1 through duration of treatment, an expected average of 3 cycles/9 weeks"
        }, 
        "source": "Kolltan Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kolltan Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}